Prof Dr Ryszard Pluta | Neuroscience | Best Researcher Award

Prof Dr Ryszard Pluta | Neuroscience | Best Researcher Award

MD.,PhD at  Medical University of Lublin , Poland

Dr. Ryszard Pluta is a distinguished neurologist and neuroscientist, with a medical degree from the Medical Academy in Lublin (1977) and a Ph.D. from the Polish Academy of Sciences (1983). He has served as a Professor at the Mossakowski Medical Research Institute and held prestigious postdoctoral fellowships at the NIH and NYS Institute for Basic Research. A recognized expert in brain ischemia and Alzheimer’s disease, Dr. Pluta has published extensively, including multiple influential books on the subject. He is a recipient of numerous awards and is an active member of several professional societies. His significant contributions to understanding the links between ischemia and Alzheimer’s have established him as a leading figure in neuropathology.

Profile:

Scopus 

Education 🎓

Ryszard Pluta earned his medical degree from the Medical Academy in Lublin (1971-1977) and attended Humboldt University in Berlin (1975) and the University of Cologne (1976). He completed his Ph.D. at the Polish Academy of Sciences in Warsaw (1983). He became an Associated Professor in 1992 and a full Professor in 2004 at the Mossakowski Medical Research Institute, Polish Academy of Sciences.

Work Experience 💼

Dr. Pluta has held prestigious positions, including postdoctoral fellowships at the NIH in Bethesda, USA (1986-1988), and the NYS Institute for Basic Research in New York (1988-1989). He has been a Visiting Professor at several renowned institutions, including the Max-Planck Institute for Neurological Research and Charles University in Prague.

Skills 🧠

With extensive expertise in neuropathology and neurochemistry, Dr. Pluta specializes in brain ischemia and Alzheimer’s disease research. His skills encompass project management, collaboration with international research teams, and contributions to clinical studies in the field of neuroscience.

Awards and Honors 🏆

Dr. Pluta has received numerous accolades, including recognition from the Polish Association of Neuropathologists (1980, 1986) and the Polish Academy of Sciences (1982, 1989, 1992). He was also honored by the International Brain Research Organization (1997) and the Alzheimer’s Association in Chicago (1998).

Membership 🤝

He is an active member of various professional organizations, including the Polish Association of Neuropathologists and the International Society of Neuropathology. Dr. Pluta is recognized among the World’s Top 2% scientists by Stanford University.

Teaching Experience 📚

Dr. Pluta has contributed to the academic community through teaching positions at various universities, where he has shared his knowledge and expertise in neuropathology and neuroscience with students and researchers.

Research Focus 🔬

His research focuses on brain ischemia, its relationship with Alzheimer’s disease, and associated neuropathological changes. He has made significant contributions, such as the documentation of identical changes in ischemic brains and those affected by Alzheimer’s, and the exploration of potential therapeutic approaches involving β-amyloid peptide.

 

Publications:

  • Alpha-, Beta-, and Gamma-Secretase, Amyloid Precursor Protein, and Tau Protein Genes in the Hippocampal CA3 Subfield in an Ischemic Model of Alzheimer’s Disease with Survival up to 2 Years
    • Year: 2024
    • Journal: Journal of Alzheimer’s Disease
  • Trans- and Cis-Phosphorylated Tau Protein: New Pieces of the Puzzle in the Development of Neurofibrillary Tangles in Post-Ischemic Brain Neurodegeneration of the Alzheimer’s Disease-like Type
    • Year: 2024
    • Journal: International Journal of Molecular Sciences
  • A Look at the Etiology of Alzheimer’s Disease based on the Brain Ischemia Model
    • Year: 2024
    • Journal: Current Alzheimer Research
  • Apoptosis, Autophagy, and Mitophagy Genes in the CA3 Area in an Ischemic Model of Alzheimer’s Disease with 2-Year Survival
    • Year: 2024
    • Journal: Journal of Alzheimer’s Disease
  • Ischemia-Reperfusion Programming of Alzheimer’s Disease-Related Genes—A New Perspective on Brain Neurodegeneration after Cardiac Arrest
    • Year: 2024
    • Journal: International Journal of Molecular Sciences
  • LRP1 and RAGE Genes Transporting Amyloid and Tau Protein in the Hippocampal CA3 Area in an Ischemic Model of Alzheimer’s Disease with 2-Year Survival
    • Year: 2023
    • Journal: Cells
  • The Dual Role of Autophagy in Postischemic Brain Neurodegeneration of Alzheimer’s Disease Proteinopathy
    • Year: 2023
    • Journal: International Journal of Molecular Sciences
  • Preservation of Biomarkers Associated with Alzheimer’s Disease (Amyloid Peptides 1-38, 1-40, 1-42, Tau Protein, Beclin 1) in the Blood of Neonates after Perinatal Asphyxia
    • Year: 2023
    • Journal: International Journal of Molecular Sciences
  • Apitherapy in Post-Ischemic Brain Neurodegeneration of Alzheimer’s Disease Proteinopathy: Focus on Honey and Its Flavonoids and Phenolic Acids
    • Year: 2023
    • Journal: Molecules
  • Post-Ischemic Permeability of the Blood–Brain Barrier to Amyloid and Platelets as a Factor in the Maturation of Alzheimer’s Disease-Type Brain Neurodegeneration
    • Year: 2023
    • Journal: International Journal of Molecular Sciences

Dr. Amira Boseila | Neuroscience| Best Researcher Award

Dr. Amira Boseila | Neuroscience| Best Researcher Award🏆


Lecturer at Sinai University,Egypt🎓

Dr. Amira Abdel Halim Hamada Boseila is a full-time lecturer in Pharmaceutical Sciences at Sinai University, Egypt, where she teaches advanced courses in drug delivery systems and pharmaceutics. She also serves as a post-doctoral researcher at the National Organization for Drug Control and Research (NODCAR) and the Egyptian Drug Authority. With a PhD from Cairo University, her research focuses on nanomedicine, drug targeting, and innovative drug delivery systems. Dr. Boseila has contributed to several impactful publications and is actively involved in various research projects aimed at enhancing therapeutic strategies.

 

Professional Profile 

🎓 Education

Dr. Amira Abdel Halim Hamada Boseila holds a Doctor of Philosophy in Pharmaceutical Sciences from the Faculty of Pharmacy at Cairo University, awarded in February 2020, with a thesis focused on the utility of nanocarriers for targeted delivery of an antiviral drug to the liver. She also earned a Master of Pharmaceutical Sciences from Cairo University in December 2013, where her thesis was centered on the formulation and evaluation of a modified nasal drug delivery system for the antiemetic drug ondansetron. Additionally, she completed a Total Quality Management Diploma at the American University of Cairo in 2009, further enhancing her expertise in quality control management. Her academic journey began with a Bachelor of Pharmaceutical Sciences from Cairo University, graduating in May 2007 with a grade of very good. She attended La Rose De Lisieux/Language School in Dokkie, where she completed her high school education with a focus on science from September 1990 to June 2002.

 

🏢 Work Experience

Full-time lecturer at the Faculty of Pharmacy, Sinai University since September 2022, and post-doctoral researcher at NODCAR and the Egyptian Drug Authority since July 2020. Previously held positions as lead quality control specialist and head of the Comparative Dissolution Unit. Guest lecturer on drug targeting at Ain Shams University since October 2020

🧬 Skills

Expertise in novel drug delivery systems, nanomedicine, drug targeting, pharmacokinetics, comparative dissolution studies, and quality by design

Awards and Honors 🏆

Recognized for contributions to pharmaceutical research through impactful publications and ongoing collaborations with prestigious institutions, including funded research projects from the University of Hail and Misr El Kheir Foundation

🔬 Research Focus

Dedicated to advancing nanomedicine and innovative drug delivery systems, with a focus on developing targeted therapies and modified release dosage forms. Actively involved in projects aimed at repurposing anti-inflammatory agents and formulating virucidal throat sprays

📚 Publication 

  • Impact of Lyophilized Milk Kefir-Based Self-Nanoemulsifying System on Cognitive Enhancement via the Microbiota–Gut–Brain Axis
    Author: Amira Boseila
    Citation: MDPI, 2023
  • Throat Spray Formulated with Virucidal Pharmaceutical Excipients as an Effective Early Prophylactic or Treatment Strategy Against Pharyngitis Post-Exposure to SARS-CoV-2
    Author: Amira Boseila
    Citation: ScienceDirect, 2024
  • Antidepressive and Cardioprotective Effects of Self-Nanoemulsifying Self-Nanosuspension Loaded with Hypericum Perforatum on Post-Myocardial Infarction Depression in Rats
    Author: Amira Boseila
    Citation: Springer, 2022
  • Recent Advances in Adsorptive Nanocomposite Membranes for Heavy Metals Ion Removal from Contaminated Water: A Comprehensive Review
    Author: Amira Boseila
    Citation: MDPI, 2023
  • Iron Oxide Nanoparticles-Plant Insignia Synthesis with Favorable Biomedical Activities and Less Toxicity, in the “Era of the-Green”: A Systematic Review
    Author: Amira Boseila
    Citation: NIH, 2023
  • In Silico and In Vitro Studies for Benzimidazole Anthelmintics Repurposing as VEGFR-2 Antagonists: Novel Mebendazole-Loaded Mixed Micelles with Enhanced Dissolution and Anticancer Activity
    Author: Amira Boseila
    Citation: PubMed, 2023
  • Superiority of DEAE-Dx-Stabilized Cationic Bile-Based Vesicles over Conventional Vesicles for Enhanced Hepatic Delivery of Daclatasvir
    Author: Amira Boseila
    Citation: Molecular Pharmaceutics, 2023
  • Design of Bile-Based Vesicles (BBVs) for Hepatocytes Specific Delivery of Daclatasvir: Comparison of Ex-Vivo Transenterocytic Transport, In-Vitro Protein Adsorption Resistance, and HepG2 Cellular Uptake of Charged and β-Sitosterol Decorated Vesicles
    Author: Amira Boseila
    Citation: PubMed, 2023
  • Preparation and Characterization of Thermosensitive Mucoadhesive In-Situ Gels for Nasal Delivery of Ondansetron Hydrochloride
    Authors: A.A. Boseila, A.Y. Abdel-Reheem, G. Abdelbary
    Citation: Al-Azhar Journal of Pharmaceutical Sciences, 2014

 

Dr Alexandros Kanellopoulos | Neuroscience | Best Researcher Award

Dr Alexandros Kanellopoulos Neuroscience | Best ResearcherAward  🏆

Principal Scientist of Cognitive Health at DSM-Firmenich, RD Innovation
Switzerland🎓

Alexandros Kanellopoulos is a seasoned Innovation Leader, Principal Scientist, and Clinical Director with over 20 years of expertise in Neuroscience, Metabolism, Early Life Nutrition (ELN), and Medical Nutrition. He has successfully led multidisciplinary teams, pioneered product innovations, and authored more than 20 high-impact publications. With 7 patents to his name, Alexandros excels in transforming scientific research into tangible solutions that meet market needs.

Professional Profile 

Education

Alexandros Kanellopoulos holds a Ph.D. in Neuroscience from Kapodistrian University, Greece (2008-2013), where his research focused on neurodevelopmental disorders. Prior to this, he completed his M.Sc. in Molecular Medicine (Neuroscience) at the same university (2005-2007), gaining advanced expertise in neuroscience and molecular biology. His academic foundation was established with a B.Sc. in Molecular Biology and Genetics from Dimocritus University of Thrace, Greece (2000-2005), where he developed a strong background in genetics and molecular biology.

Work Experience

In his current role as Global Principal Scientist & Clinical Director at DSM-Firmenich (2023-Present), Alexandros oversees scientific activities, driving innovation in dietary supplements and medical nutrition. Prior to this, he worked as an R&D Innovation Scientist and Project Manager at Nestle SA (2022-2023), leading the development of brain health products for Early Life Nutrition. In 2023, he also held the position of Medical, Scientific & Regulatory Affairs Manager at Nestle Nutrition, focusing on market communication and regulatory compliance. Alexandros previously served as Group Leader, Early Life Brain Metabolism at the University of Lausanne (2020-2022) and as Senior Scientist in Early Life Neuroscience (2016-2020), where he pioneered research in neurodevelopmental disorders.

Skills 

Alexandros is highly skilled in Innovation & Product Development, leading projects from concept to market. He is an expert in Clinical Research & Protocol Design, managing complex preclinical and clinical trials. His ability to lead multidisciplinary teams and drive Cross-functional Collaboration is complemented by his talent for Stakeholder Engagement & Market Alignment, ensuring alignment between research innovations and market needs. His Strategic Thinking, Problem-solving, and Emotional Intelligence are key to his success in high-impact research and business projects.

Awards & Honors

Throughout his career, Alexandros has earned more than 15 research awards, securing CHF 2.5 million in research funding. He has been awarded 7 patents as an inventor, reflecting his contributions to innovation in neuroscience and nutrition. In addition, he has delivered over 40 invited presentations at international conferences, establishing himself as a respected thought leader in his field.

 Membership 

Alexandros contributes to the scientific community as a Reviewer for leading neuroscience journals and serves as an Editor in scientific publications, ensuring the dissemination of high-quality research.

Teaching Experience

Alexandros is also an experienced educator, having delivered lectures in Neuroscience and Medical Sciences at the University of Lausanne and Kapodistrian University, Athens. In his academic roles, he has mentored over 20 junior scientists, fostering the next generation of researchers and innovators.

Research Focus

Alexandros’ research centers on Early Life Nutrition and its role in brain development. He is particularly focused on Neurodevelopmental Disorders such as Autism and Fragile X Syndrome. His work on Brain Energy Metabolism and Mitochondrial Function provides insights into neurotransmission and social behavior. Alexandros has also designed Preclinical and Clinical Research aimed at developing nutritional solutions to address these complex medical challenges.

Publications : 

  • Activation of the 5-HT1A Receptor by Eltoprazine Restores Mitochondrial and Motor Deficits in a Drosophila Model of Fragile X Syndrome
    🧠 International Journal of Molecular Sciences – 2024
    DOI: 10.3390/ijms25168787
  • Aralar Sequesters GABA into Hyperactive Mitochondria, Causing Social Behavior Deficits
    🧬 Cell – 2020
    DOI: 10.1016/j.cell.2020.02.044
  • Conserved Tao Kinase Activity Regulates Dendritic Arborization, Cytoskeletal Dynamics, and Sensory Function in Drosophila
    🔬 The Journal of Neuroscience – 2020
    DOI: 10.1523/jneurosci.1846-19.2020
  • Domain-Specific Cognitive Impairments in Humans and Flies With Reduced CYFIP1 Dosage
    🧩 Biological Psychiatry – 2019
    DOI: 10.1016/j.biopsych.2019.04.008
  • SynGO: An Evidence-Based, Expert-Curated Knowledge Base for the Synapse
    🧠 Neuron – 2019
    DOI: 10.1016/j.neuron.2019.05.002
  • Mitochondrial Dysfunction in Autism Spectrum Disorder: Clinical Features and Perspectives
    🧠 Current Opinion in Neurobiology – 2017
    DOI: 10.1016/j.conb.2017.05.018
  • Autism Spectrum Disorders: Translating Human Deficits into Mouse Behavior
    🐁 Neurobiology of Learning and Memory – 2015
    DOI: 10.1016/j.nlm.2015.07.013
  • Learning and Behavioral Deficits Associated with the Absence of the Fragile X Mental Retardation Protein: What a Fly and Mouse Model Can Teach Us
    🧠 Learning & Memory (Cold Spring Harbor, N.Y.) – 2014
    DOI: 10.1101/lm.035956.114
  • Learning and Memory Deficits Resulting from Reduction of the Fragile X Mental Retardation Protein: A Metabotropic Glutamate Receptor-Mediated Inhibition of cAMP Signaling in Drosophila
    🧠 The Journal of Neuroscience – 2012
    DOI: 10.1523/JNEUROSCI.1347-12.2012
  • Selective Serotonin Reuptake Inhibitors for the Treatment of Hypersensitive Esophagus: A Randomized, Double-blind, Placebo-controlled Study
    💊 The American Journal of Gastroenterology – 2011
    DOI: 10.1038/ajg.2011.179